Novel Peptide Ligand

Design and production from a single source, Serox customized peptide service
Discover More

What is Peptide Ligand Affinity Chromatography?

Peptide Ligand Affinity Chromatography (PLAC) is a specialized technique used to isolate or purify proteins, peptides, or other biomolecules based on their binding affinity to a specific peptide ligand. In this method, a column is packed with a matrix that has a specific peptide ligand attached to it. The process exploits the high-affinity binding interaction between the peptide ligand and its corresponding target protein or molecule, allowing for selective purification. 1. Ligand Immobilization: A peptide ligand is covalently attached to a stationary phase (usually a resin or solid support) inside a chromatography column. This peptide is designed to specifically interact with a target molecule (like a protein, enzyme, or receptor). 2. Sample Application: A mixture of proteins or biomolecules (the sample) is loaded onto the column. If the target molecule has a high affinity for the peptide ligand, it will bind to it, while other non-binding molecules will flow through. 3. Washing: After loading the sample, the column is washed to remove any non-specifically bound or unbound molecules. This step ensures that only molecules with high specificity for the peptide ligand stay attached to the column. 4. Elution: The target protein or molecule is then eluted from the column by changing conditions (like pH or ionic strength) or by adding a competing molecule (like excess peptide ligand or a similar molecule). This breaks the interaction, allowing the target to be released from the column and collected. 5. Purification: The eluted target can now be further analyzed or purified, depending on the goal.

What is the Novel Peptide Ligand Technology for Therapeutic Antibody and Protein Purification?

The growing demand for therapeutic biologics, including monoclonal antibodies (mAbs) and non-antibody proteins, highlights the urgent need for efficient and scalable downstream purification technologies. While upstream production methods have advanced significantly, purification processes still depend heavily on Protein A/G and antibody-based affinity chromatography. Although effective in certain applications, these conventional ligands face significant limitations, including high production costs, limited stability under harsh cleaning conditions, short operational lifespans, and vulnerability to proteolytic degradation. Traditional affinity ligands—such as antibodies, antibody fragments, small molecules, nucleic acid aptamers, and globular proteins like Protein A/G—are not universally suitable for all conditions. Larger ligands, including Protein A/G and antibody fragments, are particularly susceptible to proteolytic degradation, which can compromise their performance and potentially release immunogenic fragments into purified products, raising safety concerns. Meanwhile, smaller ligands like nucleic acid aptamers (short single-stranded DNA or RNA oligonucleotides) and small molecules, while offering specificity, often lack robustness in complex biological environments, suffer from non-specific interactions with host cell proteins, or require extensive chemical modifications to enhance their stability. These inherent challenges underscore the need for innovative affinity ligands that combine robustness, scalability, and specificity to meet the evolving demands of biologics purification. Our peptide-based affinity ligands are engineered to address these limitations, offering superior performance and reliability across diverse bioprocessing conditions.

Innovative Solutions for Purification of Biologics with Peptide Ligands

Our groundbreaking technology is based on the development of novel protease-resistant peptide ligands tailored for therapeutic biologics purification. These ligands provide a transformative alternative to conventional affinity purification methods by offering the following unparalleled advantages: » Cost-Effectiveness: Our peptide ligands reduce overall costs by eliminating the need for expensive protease inhibitors and providing a more economical alternative to Protein A/G chromatography. » Enhanced Stability, Selectivity, Affinity, and Yield: Immobilized on agarose-based chromatographic supports via stable amide or thioether bonds, these ligands offer exceptional chemical stability, superior binding efficiency, and high selectivity. This ensures high recovery rates and unparalleled purity of target proteins and antibodies, even under low-stringency conditions. » Extended Matrix Lifespan: The protease-resistant design significantly increases the durability of purification matrices, reducing replacement frequency and lowering operational costs. » Protease Resistance: These ligands withstand degradation by proteolytic enzymes, such as trypsin and α-chymotrypsin, maintaining their binding performance and preventing the release of immunogenic fragments into purified products. » While Protein A/G chromatography has revolutionized antibody purification, comparable solutions for purifying diverse biologics in their native, active conformation are limited or come with certain drawbacks. » Our innovative peptide ligand technology addresses this challenge, enabling robust, selective, and scalable purification of a wide range of therapeutic proteins, such as enzymes, hormones, and other biologics, while preserving their native, active state under mild or low elution conditions. » By combining rational design, high-throughput screening, and systematic validation, we provide customized affinity capture solutions that are tailored to the specific needs of your downstream bioprocessing workflows. These solutions enhance process robustness, reduce manufacturing costs, and accelerate development timelines for your pharmaceutical pipeline. » With our advanced peptide ligand technology, you can overcome the challenges of biologics purification, ensuring the consistent delivery of high-quality therapeutic products to patients worldwide.

Peptide Ligands for Affinity Chromatography – Precise Binding. Proven Performance.

Engineered Peptides for Selective and Efficient Biomolecule Capture 

Serox GmbH is your specialized partner for the development and production of synthetic peptide ligands used in affinity purification. Our custom-designed peptides enable highly specific binding, excellent reproducibility, and scalable manufacturing – ideal for biopharmaceutical downstream processing and research applications. 

Applications & Advantages 

  • Targeted Binding – Tailored to specific proteins, antibodies, or receptors 
  • Antibody-Free – Alternative to biological ligands (e.g., protein A/G) 
  • High Stability – Resistant to pH shifts and regeneration conditions 
  • Reusable – Efficient over multiple cycles 
  • Versatile Use – Suitable for column chromatography, beads, and membranes 

Custom Ligand Development Workflow 

  • Target Analysis – Identify epitope or binding domain 
  • Peptide Design – In silico prediction + motif screening 
  • Synthesis & Purification – Up to >98% purity 
  • Functionalization – Coupling to resin or solid phase 
  • Validation – Binding assays and application support 

Why Choose Synthetic Peptide Ligands? 

  • Chemically defined – Batch consistency, no animal origin 
  • Scalable production – Ideal for industrial applications 
  • Stable & robust – Withstands cleaning/regeneration cycles 
  • Cost-effective – Lower long-term cost vs. antibodies 
  • Fully customizable – Sequence, spacer, immobilization method 

Use Cases & Target Areas 

  • Affinity purification of monoclonal antibodies (mAbs) 
  • Isolation of viral particles or exosomes 
  • Protein complex capture 
  • Biomarker enrichment from serum or lysates 

Let’s Develop Your Ligand 

Whether you need a peptide ligand for a novel therapeutic protein or wish to replace expensive biological ligands – Serox GmbH supports your project from feasibility to final implementation. 

Contact us for a free initial consultation: 

Email: inquiry@serox.com | Phone: +49 (0)621 789 588 33 

Typical delivery time: 3–5 weeks from project start 

GMP-compliant options available 

Take Your Purification to the Next Level 

With custom peptide ligands from Serox GmbH, you gain full control, high selectivity, and consistent performance – designed and produced in Germany.